Q-omics provides the consensus-scored MIR2909 profile across patient tissues and cancer cell-line models. MIR2909 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, MIR2909 is differentially expressed in 3, with the highest sampling consensus in READ. Additionally, MIR2909 RNA expression shows 7,246 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUAD, READ, and LSCC as cancer lineages where MIR2909 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR2909 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR2909 survival associations across molecular data types. MIR2909 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR2909 RNA expression–survival associations across cancer types. High MIR2909 expression shows unfavorable associations in HNSC, UCEC, UCS and CHOL, but favorable associations in LUAD and LAML. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for MIR2909 RNA expression.
This table summarizes MIR2909 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in READ for RNA.
This table ranks reproducible tumor–normal expression differences for MIR2909. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR2909 shows higher tumor expression in READ, HNSC and STAD. The READ box plot shows higher MIR2909 RNA expression in tumor versus normal tissue (log2 FC = +0.635, t-test p = .026).
This table shows molecular features associated with MIR2909 in patient tissues and cancer cell lines. In patient samples, MIR2909 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
